These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29194805)

  • 1. Efficacy of ustekinumab in palmoplantar pustulosis.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
    Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
    J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases.
    Hu W; Wang Y; Zhang S; Wu X; Lian C
    J Dermatol; 2024 May; 51(5):e151-e153. PubMed ID: 38031884
    [No Abstract]   [Full Text] [Related]  

  • 5. Refractory Palmoplantar Pustular Psoriasis Treated With High-Dose Ustekinumab After Initial Failure.
    Bohdanowicz M; Sajic D
    J Cutan Med Surg; 2019; 23(1):102-104. PubMed ID: 30141337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
    Vergou T; Moustou AE; Antoniou C
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.
    Garber C; Rosmarin D; Nguyen B; Goodarzi M; Shinagare S; Jessup C; Madani A; Au SC; Hasanain A
    Dermatol Online J; 2017 Mar; 23(3):. PubMed ID: 28329515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 9. Clearance of annular pustular psoriasis with ustekinumab.
    Schnabel V; Broekaert SMC; Schön MP; Mössner R
    Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
    [No Abstract]   [Full Text] [Related]  

  • 10. Response of superimposed linear psoriasis to ustekinumab: A case report.
    Weng HJ; Tsai TF
    Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
    [No Abstract]   [Full Text] [Related]  

  • 11. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
    Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
    Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of ustekinumab in a psoriasis patient with human T-cell leukemia/lymphotropic virus type 1 infection.
    Kazama M; Umezawa Y; Itoh M; Nobeyama Y; Ito T; Kikuchi S; Yanaba K; Asahina A; Nakagawa H; Ogasawara Y
    J Dermatol; 2017 Nov; 44(11):1334-1335. PubMed ID: 27864824
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 16. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
    Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
    [No Abstract]   [Full Text] [Related]  

  • 17. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 18. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 19. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
    Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
    Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
    [No Abstract]   [Full Text] [Related]  

  • 20. Worsening of Psoriatic Arthritis After Ustekinumab Treatment.
    Onsun N; Yalcin B; Sallahoglu K; Rezvani A
    Am J Ther; 2018; 25(3):e381-e382. PubMed ID: 29189317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.